Onconetix, Inc. (ONCO) and OcuvexTherapeutics, Inc. announced the mutual termination of their merger agreement, dated July 16, 2025. The companies have jointly determined that pursuing independent paths is in the best interests of their respective stakeholders.
Anthony Amato, CEO of Ocuvex, said: "The decision does not impact Ocuvexs momentum or our commitment to patients. We are excited to announce that Ocuvex has received its New Jersey state pharmaceutical license, and the commercial launch of Omlonti will commence in the coming weeks."
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.